APA (7th ed.) Citation

LA, K., F, A., SAH, d. P., M, P., W, W., KR, E., . . . ECW, B. (2026). Preclinical Comparison of Two CD3xB7H4 Bispecific Antibodies for Solid Tumor Therapy Reveals CD3 Affinity-Dependent Potency and Tolerability Tradeoffs. Molecular cancer therapeutics. https://doi.org/10.1158/1535-7163.MCT-26-0054

Chicago Style (17th ed.) Citation

LA, Koopman, et al. "Preclinical Comparison of Two CD3xB7H4 Bispecific Antibodies for Solid Tumor Therapy Reveals CD3 Affinity-Dependent Potency and Tolerability Tradeoffs." Molecular Cancer Therapeutics 2026. https://doi.org/10.1158/1535-7163.MCT-26-0054.

MLA (9th ed.) Citation

LA, Koopman, et al. "Preclinical Comparison of Two CD3xB7H4 Bispecific Antibodies for Solid Tumor Therapy Reveals CD3 Affinity-Dependent Potency and Tolerability Tradeoffs." Molecular Cancer Therapeutics, 2026, https://doi.org/10.1158/1535-7163.MCT-26-0054.